Literature DB >> 31448649

Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea.

Arvind Dasari1, Vijay N Joish2, Raul Perez-Olle3, Sam Dharba2, Kavitha Balaji3, Daniel M Halperin1.   

Abstract

Objectives: We estimated the indirect costs of work productivity burden from carcinoid syndrome diarrhea (CSD) among employed, insured adults in the United States.
Methods: Retrospective cohort study of patients ≥18 years old with CS who did and did not have CSD (2014-2016). Eligible patients had continuous health plan enrollment for ≥12 months prior to their first CS claim and for ≥30 days after. Univariate analyses of clinical and work productivity outcomes and indirect costs were conducted. Multivariate analyses examined associations of CSD with work productivity measures, controlling for baseline characteristics.
Results: A total of 1,880 patients with CS were eligible, including 577 with CSD and 1,303 with CS only. Baseline characteristics were generally similar. Patients with CSD missed half of eligible workdays (median 56%, 146/260); those with CS-only missed one-third (38%, 100/260). Work productivity was lower and the associated costs were higher in the presence of CSD. Patients with CSD had more absenteeism, short-term disability, and lost workdays which translated into incremental mean costs of $16,679 greater than those with CS only.
Conclusion: Indirect costs related to work productivity losses among adults with CSD are significant, which further add to the burden of CSD to society.

Entities:  

Keywords:  Carcinoid syndrome; carcinoid syndrome diarrhea; indirect costs; neuroendocrine tumors; work productivity

Year:  2019        PMID: 31448649     DOI: 10.1080/14737167.2019.1660646

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  2 in total

1.  A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.

Authors:  I-Wen Pan; Daniel M Halperin; Bumyang Kim; James C Yao; Ya-Chen Tina Shih
Journal:  Pharmacoeconomics       Date:  2021-08-11       Impact factor: 4.558

2.  Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study.

Authors:  Matthew H Kulke; Hagen F Kennecke; Kris Murali; Vijay N Joish
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.